Yahoo Web Search

Search results

  1. Pfizer prioritizes the health and well-being of people and the planet to deliver breakthroughs around the world in a responsible way. Learn more in Pfizers 2023 Impact Report Behind the Science Feature

  2. COMIRNATY is the first COVID-19 vaccine to be granted approval by the FDA. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210823005499/en/ The vaccine has been available in the U.S. under Emergency Use Authorization (EUA) since December 11, 2020 (as the Pfizer-BioNTech COVID-19 Vaccine).

  3. en.wikipedia.org › wiki › PfizerPfizer - Wikipedia

    Pfizer Inc. (/ ˈ f aɪ z ər / FY-zər) is an American multinational pharmaceutical and biotechnology corporation headquartered at The Spiral in Manhattan, New York City. The company was established in 1849 in New York by two German entrepreneurs, Charles Pfizer (1824–1906) and his cousin Charles F. Erhart (1821–1891).

  4. Pfizer Inc. and BioNTech SE announced today they have begun an evaluation of the safety and immunogenicity of a third dose of the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) to understand the effect of a booster on immunity against COVID-19 caused by the circulating and potential newly emerging SARS-CoV-2 variants.

  5. Aug 23, 2021 · August 23, 2021. Español. Today, the U.S. Food and Drug Administration approved the first COVID-19 vaccine. The vaccine has been known as the Pfizer-BioNTech COVID-19 Vaccine, and will now be...

  6. The PfizerBioNTech COVID-19 vaccine, sold under the brand name Comirnaty, is an mRNA-based COVID-19 vaccine developed by the German biotechnology company BioNTech. For its development, BioNTech collaborated with the American company Pfizer to carry out clinical trials, logistics, and manufacturing.

  7. Jun 25, 2022 · Saturday, June 25, 2022 - 10:00am. View pdf copy Copy to clipboard Open in tab. Omicron-adapted monovalent candidate given as a fourth booster dose elicited a 13.5 and 19.6-fold increase in neutralizing geometric titers against Omicron BA.1 at 30 µg and 60 µg dose levels; bivalent vaccine candidate exhibited a 9.1 and 10.9-fold increase ...

  1. People also search for